Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Hemlibra off to a flyer as Roche raises 2019 forecasts

Hemlibra off to a flyer as Roche raises 2019 forecasts

It’s looking likely to overtake Roche’s older breast cancer Perjeta (pertuzumab), which rose 41% to CHF 868m in the quarter and has been another big growth driver for the

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug trastuzumab) and Perjeta (pertuzumab), and have disease progression after Kadcyla treatment. ... That is however well behind the $7bn and $2.8bn added to the company’s coffers by Herceptin and Perjeta.

Biosimilar Herceptin helps Roche gain new Perjeta recommendation

Biosimilar Herceptin helps Roche gain new Perjeta recommendation now recommendation of a new use for Perjeta will make the NHS an early adopter. ... Richard Erwin, Roche UK's general manager (pictured) said: “Roche has worked closely with NICE and other health stakeholders to help make Perjeta available as quickly

Roche submits Kadcyla for FDA Real-Time review

Roche submits Kadcyla for FDA Real-Time review Herceptin and follow-up Perjeta are already approved for neoadjuvant use in this indication, but it doesn’t always clear away all tumour tissue, which could dramatically increase the risk of

Ocrevus helps Roche shrug off biosimilars in 2018

Ocrevus helps Roche shrug off biosimilars in 2018 All told, new products accounted for 90% of Roche’s sales growth in 2018, with another big boost provided by the company’s breast cancer drug Perjeta (pertuzumab), up 27% to

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics